Autolus Therapeutics (NASDAQ:AUTL) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a research note released on Monday morning,Benzinga reports. They currently have a $9.00 price target on the stock.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $3.51 on Monday. Autolus Therapeutics has a 1 year low of $3.06 and a 1 year high of $7.45. The company has a market cap of $933.98 million, a price-to-earnings ratio of -3.03 and a beta of 2.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.55 and a current ratio of 18.55. The firm has a fifty day moving average of $3.98 and a 200-day moving average of $4.00.

Hedge Funds Weigh In On Autolus Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Avoro Capital Advisors LLC bought a new position in Autolus Therapeutics in the 1st quarter valued at about $78,765,000. Armistice Capital LLC grew its position in Autolus Therapeutics by 33.8% in the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after buying an additional 1,578,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Autolus Therapeutics by 82.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock valued at $35,020,000 after buying an additional 2,487,778 shares in the last quarter. Affinity Asset Advisors LLC grew its position in Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after buying an additional 925,000 shares in the last quarter. Finally, Great Point Partners LLC grew its position in Autolus Therapeutics by 195.0% in the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after buying an additional 2,275,000 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.